Experts in the management of diffuse large B-cell lymphoma (DLBCL) discuss the use of novel CD19-antibody mono- and combination therapies to treat relapsed/refractory subpopulations.
EP. 1: Current Treatment Approach to Relapsed/Refractory DLBCL
Watch
EP. 2: CD19-Targeted CAR T-Cell Therapy in Managing DLBCL
EP. 3: CD19-Targeted MAbs in Relapsed/Refractory DLBCL
EP. 4: Transplant Ineligibility: Anti-CD19 Combination Therapy
EP. 5: L-MIND Combination Therapy Dosing Schedule
EP. 6: Re-MIND Versus L-MIND Regimen
EP. 7: CD19 and CD20 Antibodies in Development
EP. 8: The Future of DLBCL Management
EP. 9: Newly Diagnosed Relapsed/Refractory DLBCL
EP. 10: CAR T: CD19-Targeted Therapy in R/R DLBCL
EP. 11: Treatment of R/R DLBCL: CD19-Targeted Monoclonal Antibodies
EP. 12: L-MIND Study: R/R DLBCL
EP. 13: Future Directions for R/R DLBCL